GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Volume 17, Issue 5, on May 1, 2025, titled "Oxytocin modulates insulin and GLP-1 secretion in pancreatic islets." ...

The global surge in diabetes cases is a key factor propelling the artificial pancreas device market, as a larger patient base fuels the need for effe ...

Among a plethora of weight-management plans and dietary charts (namely, keto, dash, sirtfood, paleo or crash diet), climbing ...

GLP-1 inhibits glucagon release, which is a hormone that raises blood sugar levels. GLP-1 prolongs gastric emptying and leads ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize ...

A study explored glucagon metabolism in humans with and without Type 1 diabetes using stable glucagon tracers. Findings ...

Traditionally, blood sugar regulation has been attributed to the hormones insulin and glucagon, both produced by the pancreas. Insulin lowers blood glucose by promoting its uptake into cells ...

Traditionally, blood sugar regulation has been attributed to the hormones insulin and glucagon, both produced by the pancreas. Insulin lowers blood glucose by promoting its uptake into cells ...

In 2010, Herrera and his researchers discovered that if beta cells die prematurely, the pancreatic cells responsible for producing other hormones such as glucagon, which counteracts insulin’s ...